




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/07		A3	(11) International Publication Number: WO 98/44808
			(43) International Publication Date: 15 October 1998 (15.10.98)
(21) International Application Number: PCT/US98/06941		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 8 April 1998 (08.04.98)			
(30) Priority Data: 60/042,061 9 April 1997 (09.04.97) US			
(71) Applicant: THE IAMS COMPANY [US/US]; 7250 Poe Avenue, Dayton, OH 45414 (US).			
(72) Inventor: HAYEK, Michael, G.; 926 Tammy Circle, Dayton, OH 45415-2136 (US).			
(74) Agents: HAGAN, Timothy, W. et al.; Killworth, Gottman, Hagan & Schaeff, L.L.P., Sutie 500, One Dayton Centre, One South Main Street, Dayton, OH 45402-2023 (US).		Published With international search report.	
		(88) Date of publication of the international search report: 7 January 1999 (07.01.99)	

(54) Title: PROCESS FOR ENHANCING IMMUNE RESPONSE IN ANIMALS USING β -CAROTENE AS A DIETARY SUPPLEMENT



(57) Abstract

A process for feeding a companion animal such as a dog or cat a diet containing an effective amount of β -carotene to enhance immune response and improve the overall health of the animal is provided. Preferably, the diet includes from about 1 to about 50 mg/day of β -carotene (from about 6 to about 315 mg β -carotene/kg diet). Such a diet provides sufficient β -carotene to be absorbed by the animal and supplied to the blood and blood leukocytes and neutrophils in the animal.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/06941

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/07

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 107, no. 3, 20 July 1987 Columbus, Ohio, US; abstract no. 22344, TOMITA, YOSHIFUMI ET AL: "Augmentation of tumor immunity against syngeneic tumors in mice by. beta.- carotene" XP002075757 see abstract & JNCI, J. NATL. CANCER INST. (1987), 78(4), 679-81 CODEN: JJIND8;ISSN: 0198-0157, --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

16 September 1998

Date of mailing of the international search report

02/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

A. Jakobs

INTERNATIONAL SEARCH REPORT

Intern 1al Application No

PCT/US 98/06941

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WENG ET AL.: "beta-Carotene Uptake By Plasma and Leukocytes in Dogs" THE FASEB JOURNAL, vol. 11, no. 3, 1997, page A180 XP002075747	7
Y	see the whole document ---	1-4,6,8
X	BENDRICH: "beta-Carotene and the immune response" PROC. NUTR. SOC., vol. 50, no. 2, 1991, pages 263-274, XP002075748	1,2,6
Y	see page 265, paragraph 2 - page 272, paragraph 3; figures 1,4; table 3 ---	1-4,6,8
X	NOCKELS C.F.: "Antioxidants improve cattle immunity following stress" ANIMAL FEED SCIENCE AND TECHNOLOGY, vol. 62, no. 1, 1996, pages 59-68, XP002075749 see abstract ---	1,2,6
X	ROVETA ET AL.: "BETA-CAROTENE SUPPLEMENTATION IS EFFECTIVE IN MODULATING HOST DEFENSE AS DETECTED ON A TUMOR AND HOST ORGAN IMPRINT ASSAY" MED. BIOL. ENVIRON., vol. 20, no. 2, 1992, pages 193-200, XP002075750 see abstract ---	1,2,6
X	ROVETA ET AL.: "BETA-CAROTENE: BIOMODULATING EFFECTS ON EXPERIMENTAL TUMOR CELL SPREADING" MED. BIOL. ENVIRON., vol. 21, no. 1, 1993, pages 455-459, XP002075751 see the whole document ---	1,2,6
X	SCHWATZ ET AL.: "Prevention and Inhibition of Oral Cancer in the Hamster Buccal Pouch Model Associated with Carotenoid Immune Enhancement" TUMOR BIOL., vol. 10, no. 6, 1989, pages 297-309, XP002075752 see abstract; tables 1-5 ---	1,2,6
X	BENDICH A.: "ANTIOXIDANT VITAMINS AND THEIR FUNCTION IN IMMUNE RESPONSES" ADV. EXP. MED. BIOL., vol. 262, 1990, pages 35-55, XP002075753 see page 46, paragraph 2 - page 49, paragraph 1; table 6 ---	1,2,6
	-/--	

INTERNATIONAL SEARCH REPORT

Inter: nal Application No
PCT/US 98/06941

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BURRI B.J.: "beta-Carotene and Human Health: a Review of Current Research" NUTRITION RESEARCH, vol. 17, no. 3, 1997, pages 547-580, XP002075754 see page 554, paragraph 4 - page 555, paragraph 4; table 5 ---	1,2,6
X	BIESALSKI ET AL.: "Antioxidanzien in der Ernährung und ihre Bedeutung für die anti-/prooxidative Balance im Immunsystem" IMMUNITÄT UND INFEKTION, vol. 23, no. 5, 1995, pages 166-173, XP002075755 see page 170, column 2, paragraph 2 - column 3, paragraph 1; figure 4 ---	1,2,6
X	CARLOS ET AL.: "beta-Carotene Enhances Natural Killer Cell Activity in Athymic Mice" IN VIVO, vol. 11, no. 1, 1997, pages 87-91, XP002075756 see abstract ---	1,2,6
X	EP 0 689 834 A (SERFONTEIN WILLEM JACOB) 3 January 1996 see page 3, line 31-33; claim 10; examples 1,5,12,15 -----	1-8

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/06941

Patent document
cited in search report

Publication
date

Patent family
member(s)

Publication
date

EP 0689834

A

03-01-1996


NONE



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A23K 1/00		A2	(11) International Publication Number: WO 98/44808
			(43) International Publication Date: 15 October 1998 (15.10.98)
(21) International Application Number: PCT/US98/06941		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 8 April 1998 (08.04.98)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: 60/042,061 9 April 1997 (09.04.97) US			
(71) Applicant: THE IAMS COMPANY [US/US]; 7250 Poe Avenue, Dayton, OH 45414 (US).			
(72) Inventor: HAYEK, Michael, G.; 926 Tammy Circle, Dayton, OH 45415-2136 (US).			
(74) Agents: HAGAN, Timothy, W. et al.; Killworth, Gottman, Hagan & Schaeff, L.L.P., Suite 500, One Dayton Centre, One South Main Street, Dayton, OH 45402-2023 (US).			

(54) Title: **PROCESS FOR ENHANCING IMMUNE RESPONSE IN ANIMALS USING β -CAROTENE AS A DIETARY SUPPLEMENT**



(57) Abstract

A process for feeding a companion animal such as a dog or cat a diet containing an effective amount of β -carotene to enhance immune response and improve the overall health of the animal is provided. Preferably, the diet includes from about 1 to about 50 mg/day of β -carotene (from about 6 to about 315 mg β -carotene/kg diet). Such a diet provides sufficient β -carotene to be absorbed by the animal and supplied to the blood and blood leukocytes and neutrophils in the animal.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PROCESS FOR ENHANCING IMMUNE RESPONSE IN ANIMALS
USING β -CAROTENE AS A DIETARY SUPPLEMENT

BACKGROUND OF THE INVENTION

This invention relates to a pet food supplement and
5 process for enhancing immune response and improving the overall
health of companion animals such as cats and dogs, and more
particularly to a pet food supplement and process which
includes beneficial amounts of β -carotene in the animal's diet.

Carotenoids are naturally-occurring plant pigments which
10 are absorbed in varying degrees by different species. Common
carotenoids include β -carotene, lycopene, lutein, zeaxanthin,
and astaxanthin. These carotenoids (the most extensively
studied being β -carotene) are known to play an important role
in modulating the immune system and enhancing the health of
15 these species. β -carotene is known to be a precursor to
vitamin A and converted to that vitamin by enzymes in the
bodies of certain animals including humans and dogs. However,
cats do not possess this enzyme and cannot convert β -carotene
into vitamin A.

20 β -carotene is also known to have potent antioxidant
activity and serves to protect cell membranes and organelles
from oxidative damage in certain species. However, in order to
be effective, β -carotene must be present at critical sites in
the cell such as the mitochondria, nuclei, and plasma membrane.

25 Disease prevention is important both in humans as well as
companion animals. A healthy immune system plays an important
role both in preventing and fighting disease. Some studies
have reported only low to undetectable amounts of β -carotene in
the circulating blood and organs of dogs. Further, because of
30 the known inability of cats to convert β -carotene to vitamin A,
their diets have not included β -carotene supplements.
Accordingly, there remains a need in the art for promoting a
healthy immune system in companion animals such as dogs and
cats.

-2-

SUMMARY OF THE INVENTION

The present invention meets that need by providing a process for feeding a companion animal such as a dog or cat a diet containing an effective amount of β -carotene to enhance immune response and improve the overall health of the animal. Preferably, the animal is fed a diet which includes from about 1 to about 50 mg/day of β -carotene (from about 6 to about 315 mg β -carotene/kg diet). Such a diet provides sufficient β -carotene to be absorbed by the animal and supplied to the blood and blood leukocytes and neutrophils in the animal.

Accordingly, it is a feature of the present invention to provide a pet food supplement and process for enhancing immune response and improving the overall health of companion animals such as cats and dogs by providing an effective amount of β -carotene in the diet of the animal. This, and other features and advantages of the present invention, will become apparent from the following detailed description and accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph of concentration of blood plasma β -carotene in dogs ($\mu\text{g/l}$) versus time for dogs given a single oral dose of β -carotene;

Fig. 2 is a graph of concentration of blood plasma β -carotene in dogs ($\mu\text{g/l}$) versus time for dogs given repeated doses of β -carotene;

Fig. 3 is a graph of the uptake of dietary β -carotene by blood lymphocytes ($\text{ng}/10^8$ cells) versus time from dogs fed β -carotene daily for 30 days;

Fig. 4 is a graph of the uptake of dietary β -carotene by the nuclei, mitochondria, microsomes, and cytosol of blood lymphocytes ($\text{ng}/10^8$ cells) from dogs fed β -carotene daily for 30 days;

Fig. 5 is a graph of relative (%) uptake of β -carotene by subcellular fractions of blood lymphocytes (mitochondria, microsomes, cytosol, and nuclei) from dogs fed β -carotene daily for 30 days;

-3-

Fig. 6 is a graph of uptake of dietary β -carotene by blood neutrophils from dogs (ng/ 10^8 cells) fed β -carotene daily for 30 days;

Fig. 7 is a graph of the uptake of dietary β -carotene by the nuclei (nucl), mitochondria (mito), microsomes (micro), and cytosol (cyto) of blood neutrophils from dogs fed β -carotene daily for 30 days;

Fig. 8 is a graph of relative (%) uptake of β -carotene by subcellular fractions of blood neutrophils (mitochondria, microsomes, cytosol, and nuclei) from dogs fed β -carotene daily for 30 days;

Fig. 9 is a graph of changes in concentrations of plasma β -carotene in dogs fed 0, 2, 20, or 50 mg of β -carotene daily for 8 weeks;

Fig. 10 is a graph of DTH response to PHA in dogs fed 0, 2, 20, or 50 mg of β -carotene daily for 7 weeks;

Fig. 11 is a graph of DTH response to vaccine in dogs fed 0, 2, 20, or 50 mg of β -carotene daily for 7 weeks;

Fig. 12 is a graph of changes in lymphocyte CD4 subset in dogs fed 0, 2, 20, or 50 mg of β -carotene daily for 8 weeks;

Fig. 13 is a graph of changes in plasma total Ig in dogs fed 0, 2, 20, or 50 mg of β -carotene daily for 8 weeks;

Fig. 14 is a graph of concentration of blood plasma β -carotene in cats (μ g/l) versus time for cats given a single oral dose of β -carotene;

Fig. 15 is a graph of concentration of blood plasma β -carotene in cats (μ g/l) versus time for cats given repeated doses of β -carotene;

Fig. 16 is a graph of the uptake of dietary β -carotene by blood lymphocytes (ng/ 10^8 cells) versus time from cats fed β -carotene daily for 14 days;

Fig. 17 is a graph of the uptake of dietary β -carotene by the nuclei (nucl), mitochondria (mito), microsomes (micro), and cytosol (cyto) of blood lymphocytes from cats fed β -carotene daily for 7 days;

-4-

Fig. 18 is a graph of the uptake of dietary β -carotene by the nuclei (nucl), mitochondria (mitro), microsomes (micro), and cytosol (cyto) of blood lymphocytes from cats fed β -carotene daily for 14 days;

5 Fig. 19 is a graph of changes in the relative proportion (%) of β -carotene in lymphocyte subcellular fractions in cats fed 5 mg of β -carotene day for 7 and 14 days; and

Fig. 20 is a graph of changes in the relative proportion (%) of β -carotene in lymphocyte subcellular fractions
10 (mitochondria, microsomes, cytosol, and nuclei) in cats fed 10 mg of β -carotene day for 7 and 14 days.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention uses a pet food composition which contains a source of β -carotene as a supplement in an amount of
15 between about 1 to about 50 mg/day of β -carotene (from about 6 to about 315 mg β -carotene/kg diet). Such a diet provides sufficient β -carotene to be absorbed by the animal and supplied to the blood and blood leukocytes and neutrophils in the animal. It has been found that both domestic dogs and cats are
20 able to absorb dietary β -carotene. Furthermore, circulating β -carotene is significantly absorbed by both peripheral blood lymphocytes and neutrophils in such animals. β -carotene is also distributed in the various subcellular organelles. Such β -carotene in the various organelles of leukocytes is believed
25 to (1) protect these cells from oxygen free radical attack and/or (2) directly regulate nuclear events. Thus, feeding dogs and cats effective amounts of β -carotene provides β -carotene at important cellular sites in the body tissues of the animal which may result in an up-regulation of immune function
30 and improved health in such animals.

The pet food composition can be any suitable pet food formula which also provides adequate nutrition for the animal. For example, a typical canine diet for use in the present invention may contain about 30% crude protein, about 20% fat,
35 and about 10% total dietary fiber. However, no specific ratios or percentages of these or other nutrients are required. The

-5-

β -carotene may be blended with such pet food to provide the beneficial amounts needed.

In order that the invention may be more readily understood, reference is made to the following examples which
5 are intended to illustrate the invention, but not limit the scope thereof.

Example 1 - Dogs - Blood Uptake After a Single Dose

Female Beagle dogs (18 to 19 months of age; 7 to 9 kg body weight) were used in Examples 1-3 and were fed a basal diet
10 (The Iams Co., Lewisburg, OH) which met or exceeded the requirement for all essential nutrients. Animals were housed indoors in light- (14 hr light; 10 hr dark) and temperature-controlled rooms. A test was conducted to study the uptake profile of β -carotene after a single oral dose of β -carotene.

15 To study the uptake of oral β -carotene in dogs given a single dose of β -carotene orally, dogs (n = 6/treatment) were given once perorally 0, 50, 100 or 200 mg of β -carotene (10% cold water dissolvable; BASF Corp., Ludwigshafen, Germany). The appropriate dose of β -carotene was dissolved in 5 ml of water
20 fed orally by using a feeding syringe. In order to establish appropriate sampling times, two dogs were used in a preliminary study. These dogs were fed once with 50 mg β -carotene and blood sampled at 0 (immediately prior to β -carotene feeding), 3, 6, 9, 12, 15, 18, 21 and 24 hr.

25 Blood plasma was separated by centrifugation and β -carotene concentrations were analyzed using high performance liquid chromatography (HPLC) as follows. All procedures were conducted under dim light. Duplicate aliquots of plasma, each leukocyte homogenate, and each leukocyte subcellular fraction
30 were extracted with a 1:1 mixture of diethyl ether and petroleum ether in the presence of BHT. The ether phase was removed and dried under a stream of nitrogen. The residue was reconstituted in mobile phase for the HPLC determination of β -carotene. Samples (50 μ l) were injected onto a 5 μ m spherical
35 C-18 reverse-phase column (3.9 x 150 mm; Resolve) and eluted

-6-

with a 47:47:6 (v/v/v) mixture of acetonitrile, methanol, and chloroform at a flow rate of 1.0 ml/min.

Results from this example are illustrated in Fig. 1 and show peak concentrations of β -carotene occurring between 3 and 5 6 hr post-dosing and were undetectable by 24 hr. Subsequently, blood was sampled from the remaining dogs at the same time periods. Plasma was similarly separated and analyzed by HPLC.

Concentrations of plasma β -carotene was undetectable in unsupplemented dogs at all time periods studied. In contrast, 10 there was a dose-dependent increase ($P < 0.01$) in plasma β -carotene in dogs given an oral dose of β -carotene (Fig. 1). Peak concentrations were observed at 6 hr post-dosing and were consistent in all treatment groups. Thereafter, there was a rapid decrease ($P < 0.01$) in β -carotene concentrations in all 15 β -carotene supplemented dogs. Concentrations were undetectable by 24 hr post-dosing. The half-life of plasma β -carotene was approximately 3 (50 and 100 mg doses) to 4 (100 mg dose) hours. Peak concentrations of blood β -carotene occurred earlier in dogs than in cats (see Examples 4 and 5 below). Also, 20 concentration of β -carotene in the plasma of dogs are approximately 10 to 16 fold lower than that observed in cats after adjusting for differences in body weight.

Example 2 - Dogs - Blood Uptake With Repeated Doses

In this Example, the dogs ($n = 6/\text{treatment}$) were fed daily 25 at 0800 hr for 7 consecutive days with 0, 12.5, 25, 50 or 100 mg β -carotene. The β -carotene was top-dressed on the food and fed in the morning meal. Blood was sampled once daily on day 0 (immediately prior to the first dose) and subsequently at 6 hr after each dosing (days 1 through 7). This blood sampling time 30 was chosen based on the results obtained in Example 1 which showed peak concentrations of β -carotene at 6 hr after a dose. Plasma was isolated and analyzed for concentrations of β -carotene.

Daily dosing of dogs with β -carotene for 7 days produced a 35 dose-dependent increase ($P < 0.01$) in circulating β -carotene as illustrated in Fig. 2. Dogs fed 100 mg of β -carotene showed

-7-

the steepest increase in daily concentrations of plasma β -carotene. Peak concentrations ($18 \mu\text{g/L}$) of plasma β -carotene on day 1 in dogs fed 100 mg β -carotene in this example was similar to that observed in Example 1 (Fig. 1). Concentrations of plasma β -carotene after the last dose was generally 2.5 to 4 fold higher than that observed after the first dose.

Results from this example suggest that the dog can absorb β -carotene from its diet. This finding contradicts early studies which reported trace amounts, if any, of carotene in the blood, liver and milk of dogs. However, others have reported low to moderate concentrations of β -carotene in the blood of dogs.

Example 3 - Dogs - Uptake by Blood Leukocytes

This example was designed to study the uptake of β -carotene in dogs by blood lymphocytes. The dogs ($n = 8/\text{treatment}$) were fed 0, 50 or 100 mg of β -carotene daily for 30 days. Blood was sampled from all dogs via the jugular vein on days 10, 20 and 30. Blood lymphocytes and neutrophils were separated by density gradient centrifugation. Cell numbers were enumerated. Lymphocytes and neutrophils were resuspended in PBS containing 3% sodium ascorbate as an antioxidant. An aliquot of the cell suspension was sonicated for 30 seconds to disrupt the cells. The leukocyte homogenates were extracted for HPLC analysis of β -carotene.

On day 30, a larger aliquot of blood was taken and leukocyte suspensions prepared as described above for subsequent subcellular fractionation. Cells were disrupted by sonication for 20 seconds in 5 volumes of 0.25 M sucrose. Sodium ascorbate was added as the antioxidant. The homogenate was centrifuged ($600 \times g$ for 10 min at 4°C) and the nuclear pellet separated from the supernatant. The postnuclear supernatant was centrifuged ($17,300 \times g$ for 20 min at 4°C) to separate the mitochondrial fraction. The postmitochondrial supernatant was centrifuged ($102,000 \times g$ for 60 min at 4°C) to separate the microsomal from the cytosolic fraction. Each

subcellular fraction was analyzed for β -carotene content by HPLC.

On day 0 (prior to β -carotene supplementation), concentrations of β -carotene in peripheral blood lymphocytes were undetectable in all dogs as illustrated in Fig. 3. Also, β -carotene in lymphocytes from unsupplemented dogs remained undetectable throughout the study. In contrast, β -carotene concentrations in lymphocytes from dogs fed β -carotene generally increased ($P < 0.01$) in a time-dependent manner. There was no significant treatment difference in β -carotene concentrations in lymphocytes when comparing dogs fed 50 versus 100 mg β -carotene. Concentrations of β -carotene in the lymphocytes of dogs in this example is 20 to 30 fold lower than that observed in cats (see Examples 4 and 5 below).

Figs. 4 to 8 illustrate the uptake of β -carotene by lymphocyte and neutrophil subcellular fractions. β -carotene was not detectable in the various subcellular fractions of lymphocytes obtained from unsupplemented dogs (Fig. 4). In contrast, β -carotene was taken up by all subcellular fractions of blood lymphocytes isolated from β -carotene-supplemented dogs. The cytosol fraction accounted for 52 to 62% of the total β -carotene in the lymphocytes (Fig. 5) while the nuclei contained the lowest (6 to 8%) amount of total β -carotene. The mitochondria (14 to 17%) and microsomes (16 to 23%) were intermediate between the cytosol and the nuclei. The dose of dietary β -carotene did not have a significant influence on β -carotene uptake by the subcellular fractions on day 30 of feeding. The results show that β -carotene was taken up by all lymphocyte subcellular fractions. However, β -carotene was highest in the cytosol of dogs, but was highest in the mitochondria of cats (see Examples 4-6 below). Also, concentrations of β -carotene in all the subcellular fractions of dog lymphocytes were substantially lower than that reported in cats (see Examples 4-6 below).

As with lymphocytes, blood neutrophils similarly take up β -carotene (Fig. 6). However, unlike lymphocytes, maximal uptake occurred by day 10, with no further increase in

neutrophil β -carotene concentrations observed on day 30. The cytosol, mitochondria and microsomes of blood neutrophils also showed significant uptake of β -carotene (Fig. 7). In contrast, β -carotene was not detected in the nuclei. As with blood lymphocyte subcellular fractions, β -carotene was the highest (61 to 68) in the cytosolic fraction of blood neutrophils (Fig. 8). No significant dose effect was observed.

The results indicate that the dog is able to absorb dietary β -carotene. This result is surprising as earlier studies have found only trace amounts of β -carotene in the liver and milk of dogs, and only trace to moderate amounts in the blood of dogs. Furthermore, it has been found that circulating β -carotene is significantly absorbed by both peripheral blood lymphocytes and neutrophils in the dog. β -carotene is distributed in the various subcellular organelles. β -carotene in the various organelles of leukocytes is believed to (1) protect these cells from oxygen free radical attack and/or (2) directly regulate nuclear events. Thus, feeding dogs effective amounts of β -carotene, which results in β -carotene presence at important cellular sites in the body tissue provides improved health in such dogs.

Example 4 - Dogs - Effect on Immune Response

Female Beagles (4 to 5 mo old) were supplemented daily with 0, 25, 50 or 100 mg of β -carotene to study the role of dietary β -carotene in enhancing the cell-mediated and humoral immune systems of the dog. The following parameters were assessed in all the animals or in the peripheral blood lymphocytes: (1) delayed-type hypersensitivity (DTH) against PHA (nonspecific immunity) and vaccine (specific immunity), (2) lymphocyte proliferation, (3) lymphocyte populations and (4) immunoglobulins (Ig).

β -Carotene supplementation increased plasma β -carotene concentrations in a dose-dependent manner as shown in Fig. 9 but did not influence plasma retinol or α -tocopherol. These changes generally reflected the DTH response to both the specific (vaccine) and non-specific (PHA) antigens as shown in

-10-

Figs. 11 and 10, respectively. The greatest response to PHA challenge was observed in dogs fed 50 mg of β -carotene whereas dogs fed either 20 or 50 mg of β -carotene showed significantly higher DTH response to the vaccine. Delayed type

5 hypersensitivity is strictly a cellular reaction involving T cells and macrophages without involving an antibody component. Antigen presenting cells (e.g., macrophages) present the antigen or allergen to T cells that become activated and release lymphokines. These lymphokines activate macrophages
10 and cause them to become voracious killers of the foreign invaders. Therefore, the data show a heightened cell-mediated response in dogs fed β -carotene.

β -Carotene feeding also produced significant changes in lymphocyte subsets. Compared to controls, dogs fed 20 or 50 mg
15 of β -carotene had an elevated population of CD4+ cells (wk 8) as shown in Fig. 12. Dogs fed 20 mg of β -carotene also had elevated population of CD8 cells in weeks 2 and 4. The T cells can be classified according to the expression of CD4 membrane molecules. The CD4 functions as an adhesion molecule and as a
20 co-signaling co-receptor. It plays a role in T cell activation. The CD4+ T lymphocytes recognize antigen in association with the class II MHC molecules and largely function as helper cells. The increase in T helper cell population in this study can explain the corresponding increase
25 in DTH response in dogs fed 20 to 50 mg of β -carotene.

Concentrations of IgG, IgM and total IgG (Figure 10) increased significantly in dogs fed β -carotene as early as 1 wk after dietary supplementation. Increases in Ig were dose dependent for dogs fed 0 to 20 mg of β -carotene. The highest
30 level of β -carotene (50 mg) did not produce a further increase. Dogs fed 20 mg of β -carotene consistently had the greatest antibody response for both Ig. One of the major functions of the immune system is the production of antibodies which circulates freely to protect the body against foreign
35 materials. Antibodies serve to neutralize toxins, immobilize certain microorganisms, neutralize viral activity, agglutinate

-11-

microorganisms or antigen particles and precipitate soluble antigens.

5 β -Carotene feeding did not influence mitogen-induced lymphocyte blastogenesis and IL-2 production. Lymphocytes are involved in cell-mediated immunity. Upon recognizing an antigen, lymphocytes will divide rapidly, thereby cloning themselves in preparation for combating a potential invasion. In humoral immune response, IL-2 stimulates both T helper cells and B cells to proliferate in response to antigens. It is
10 required for the clonal expansion of antigen- or mitogen-activated T cells. In cell-mediated immune response, IL-2 activates natural killer cells, stimulates thymocyte proliferation and induces cytotoxic T cell activity. It is surprising that these two immune parameters were not influenced
15 by β -carotene feeding whereas numerous others were.

Based on the results of these experiments, the dog absorbs a significant amount of β -carotene from the diet and transfers the β -carotene into the subcellular organelles of immune cells and phagocytes. In these cells, β -carotene appears to enhance
20 the immune system of the dog through enhanced cell-mediated immune responses (DTH response, shift in lymphocyte subsets) and humoral response (IgG and IgM production). Thus, supplemental dietary β -carotene promotes the immune health of dogs, which will likely translate into improved overall health.

25 Example 5 - Cats - Blood Uptake After a Single Dose

Mature female short hair Tabby cats (7 to 8 months of age; 1.5 to 2.0 kg body weight) were used for Examples 4-6 and were fed a basal diet (The Iams Co., Lewisburg, OH) which met or exceeded the requirement for all essential nutrients. Animals
30 were group-housed indoors in light- and temperature-controlled rooms. A test was conducted to study the uptake profile of β -carotene after a single oral dose of β -carotene.

To study the uptake of oral β -carotene in cats given a single dose of β -carotene orally, cats (n = 6/treatment) were
35 given once perorally 0, 10, 20 or 50 mg of β -carotene (10% cold water dissolvable; BASF Corp., Ludwigshafen, Germany). The

-12-

appropriate dose of β -carotene was dissolved in 0.6 ml of water and fed orally by using a feeding syringe. In order to establish appropriate sampling times, two cats were used in a preliminary study. These cats were fed once with 50 mg β -carotene and blood sampled at 0 (immediately prior to β -carotene feeding), 3, 6, 10, 16, 24, 30 and 36 hr.

Blood plasma was separated by centrifugation and β -carotene concentrations were analyzed using HPLC as described previously. The results from this example are illustrated in Fig. 14 and show peak concentrations of β -carotene generally occurring between 10 and 16 hr post-dosing. Subsequently, blood was sampled from the remaining cats at 0, 12, 24, 30, 36, 42, 48 and 72 hr after dosing. Plasma was similarly separated and analyzed.

Concentrations of plasma β -carotene was undetectable in unsupplemented cats at all times periods studied. In contrast, plasma β -carotene in cats given an oral dose of β -carotene generally increased ($P < 0.01$) in a dose-dependent manner (Fig. 14). Concentrations were highest ($P < 0.01$) in cats fed 50 mg β -carotene. Plasma concentrations of β -carotene in cats fed 10 or 20 mg of β -carotene were similar ($P > 0.1$). Peak concentrations were observed at 12 hr in cats given 10 or 20 mg of β -carotene, while those fed 50 mg of β -carotene showed peak concentrations at 24 hr. Concentrations declined ($P < 0.01$) subsequently in all supplemented animals to undetectable levels (10 and 20 mg group) by 72 hr. However, plasma β -carotene was still detectable (over 100 $\mu\text{g/ml}$) at 72 hr in cats fed 50 mg of β -carotene. The half-life of plasma β -carotene was 12 to 18 hr for cats fed 10 or 20 mg β -carotene group but was about 24 hr in cats fed 50 mg β -carotene.

Example 6 - Cats - Blood Uptake With Repeated Doses

In this Example, the cats ($n = 6/\text{treatment}$) were dosed daily at 0800 hr for 6 consecutive days with 0, 1, 2, 5 or 10 mg β -carotene. Blood was sampled once daily on day 0 (immediately prior to the first dose) and subsequently at 12 hr after each dosing (days 1 through 6). This blood sampling time

-13-

was chosen based on the results obtained in Example 5. Plasma was isolated and analyzed for concentrations of β -carotene.

Daily dosing of cats with β -carotene for 6 days resulted in a dose-dependent increase ($P < 0.01$) in circulating β -carotene as shown in Fig. 15. Cats fed 10 mg of β -carotene showed the steepest increase in daily changes in plasma β -carotene. In this example, the concentration of plasma β -carotene at 12 hr after the first dose ($192 \pm 58 \mu\text{g/L}$) was similar to that observed in Example 5 ($230 \pm 26 \mu\text{g/L}$; see Fig. 14). Concentrations of plasma β -carotene after the last dose was generally 1.5 to 2 fold higher than that observed after one dose.

Based on the results in this example, plasma β -carotene concentrations may continue to increase with continued supplementation. Results from this example suggest that the domestic cat readily absorbs dietary β -carotene. This finding contradicts previous reports which indicated that domestic cats are unable to absorb oral β -carotene. Cats do not possess the necessary intestinal enzyme to convert β -carotene to vitamin A. This has been suggested by some researchers as an explanation for the presence of high concentrations of β -carotene in the general circulation. However, it is very unlikely that this physiological difference has direct bearing on the cat's ability to absorb β -carotene because pigs and rodents have very low concentrations of β -carotene even though they possess intestinal β -carotene cleavage enzymes. Thus, the ability of cats to absorb dietary β -carotene as demonstrated in this example is more likely due to the presence of a β -carotene transport mechanism in the intestinal mucosa.

30 Example 7 - Cats - Uptake by Peripheral Blood Lymphocytes

This example studied the uptake of β -carotene by blood lymphocytes in cats. The cats ($n = 8/\text{treatment}$) were fed 0, 5 or 10 mg of β -carotene daily for 14 days. Blood was sampled on days 7 and 14 with the aid of a blood collection vacutainer set (Becton Dickenson, Franklin Lakes, NJ) in sedated animals (10 mg ketamine and 0.1 mg of acepromazine/kg body weight). Blood

lymphocytes and neutrophils were separated by density gradient centrifugation. Cell numbers were enumerated. Lymphocytes were resuspended in PBS containing 3% sodium ascorbate as an antioxidant. An aliquot of the cell suspension was sonicated
5 for 30 seconds to disrupt the cells. The lymphocyte homogenate was extracted for the HPLC analysis of β -carotene. Adequate numbers of neutrophils could not be obtained; therefore, no data are available in quantitating the uptake of β -carotene by circulating neutrophils.

10 A larger aliquot was used to prepare subcellular lymphocyte fractions. Lymphocytes were disrupted by sonication for 20 seconds in 5 volumes of 0.25 M sucrose. Sodium ascorbate was added as the antioxidant. The homogenate was centrifuged (600 x g for 10 min at 4°C) and the crude nuclear pellet
15 separated from the supernatant. The postnuclear supernatant obtained earlier was centrifuged (17,300 x g for 20 min at 4°C) to separate the mitochondrial fraction. The postmitochondrial supernatant was centrifuged (102,000 x g for 60 min at 4°C) to separate the microsomal from the cytosolic fraction. Each
20 subcellular fraction was analyzed for β -carotene content by HPLC.

On day 0 (prior to β -carotene supplementation), concentrations of β -carotene in peripheral blood lymphocytes were undetectable in all cats (Fig. 16). By day 7, blood
25 lymphocytes showed significant uptake ($P < 0.01$) of β -carotene, with no additional increases observed on day 14. Cats supplemented with 10 mg of β -carotene did not have higher accumulation of β -carotene in the lymphocytes. Therefore, maximal uptake of dietary β -carotene occurred by day 7 and with
30 an oral dose of 5 mg or less.

Upon subcellular fractionation of the peripheral blood lymphocytes, β -carotene was observed to be accumulated in all cell fractions as illustrated in Figs. 17 and 18. Concentrations of β -carotene were highest in the mitochondria
35 (40 to 52%), medium in the microsomes (20 to 35%) and cytosol (15 to 34%), and lowest in the nuclei (1.5 to 6%) as illustrated in Figs. 19 and 20. These relative β -carotene

-15-

profiles in lymphocyte subcellular fractions generally were not influenced by treatment dose or length of supplementation. However, β -carotene uptake in the nuclei is still significant in the lymphocytes of cats supplemented with β -carotene as compared to unsupplemented controls. Cats fed 10 mg β -carotene (Fig. 20) did not have higher concentrations of β -carotene than those fed 5 mg (Fig. 19). Also, there was no additional accumulation of β -carotene in all fractions on day 14 (Fig. 18) as compared to that of day 7 (Fig. 17).

These results are in general agreement with the data on whole lymphocytes (Fig. 16) showing that maximal β -carotene uptake occurred by day 7 of β -carotene feeding and that oral β -carotene dose of 5 mg is adequate to produce maximal uptake by lymphocytes. Maximal uptake of β -carotene in cat lymphocytes in this example also was observed by day 7, and the mitochondria also contains the highest proportion of total β -carotene.

These results show that the domestic Tabby cat is able to absorb dietary β -carotene. Furthermore, circulating β -carotene is significantly absorbed by peripheral blood lymphocytes and distributed into the various subcellular organelles, notably the mitochondria. β -carotene in the lymphocyte subcellular organelles is believed to (1) protect the lymphocytes from oxygen free radical attack and/or (2) directly regulate nuclear events. Thus, feeding domestic cats effective amounts of β -carotene which results in β -carotene presence at important cellular sites in the body tissue may result in enhanced immune function and improved health in such cats.

While certain representative embodiments and details have been shown for purposes of illustrating the invention, it will be apparent to those skilled in the art that various changes in the methods and apparatus disclosed herein may be made without departing from the scope of the invention, which is defined in the appended claims.

-16-

CLAIMS

1. A process for enhancing immune response and improving the overall health of a companion animal comprising the step of feeding said animal a diet containing an effective amount of β -carotene for a time sufficient for said β -carotene to be absorbed by said animal.
2. A process as claimed in claim 1 in which said diet includes from about 1 to about 50 mg/day of β -carotene.
3. A process as claimed in claim 1 in which said diet includes from about 6 to about 315 mg β -carotene per kg of diet.
4. A process as claimed in claim 1 wherein said companion animal is a dog.
5. A process as claimed in claim 1 wherein said companion animal is a cat.
6. A process as claimed in claim 1 in which said diet comprises about 30% crude protein, about 20% fat, and about 10% dietary fiber.
7. A process for increasing the β -carotene concentration in the circulating blood of a companion animal comprising the step of feeding said animal a diet containing an effective amount of β -carotene for a time sufficient for said β -carotene to be absorbed into the bloodstream of said animal.
8. A process for promoting immune health in a dog comprising the step of feeding said dog a diet containing an effective amount of β -carotene for a time sufficient for said β -carotene to enhance the cell-mediated immune response and humoral response of said dog.

1 / 11




FIG. 1




FIG. 2

2 / 11




FIG. 3




FIG. 4

3 / 11




FIG. 5




FIG. 6

4 / 11




FIG. 7




FIG. 8

5 / 11




FIG. 9




FIG. 10

6 / 11




FIG. 11




FIG. 12

7 / 11




FIG. 13

8 / 11




FIG. 14




FIG. 15

9 / 11




FIG. 16




FIG. 17

10 / 11




FIG. 18




FIG. 19




FIG. 20